INTI · Inhibitor Therapeutics, Inc.

Inhibitor Therapeutics, Inc. disclosed that it initiated litigation on March 30, 2026, against an institutional investor resulting from the investor's failure to fund a previously announced $3,000,000 financing. The financing, originally agreed upon on February 24, 2026, involved the sale of 12,000,000 shares of common stock and warrants to purchase up to 7,000,000 shares at a price of $0.25 per share and accompanying warrant. The lawsuit follows several attempts by the Company to secure the funds without resorting to legal action. The failure to close this transaction represents a significant liquidity event for the Company, as the expected $3,000,000 in proceeds were not received. The Company stated that more detailed information regarding the litigation will be provided in a subsequent Current Report on Form 8-K. Investors should be aware of the uncertainty surrounding the collection of these funds and the potential impact on the Company's cash position and operations.